Myriad Genetics (MYGN) Misses Q1 EPS by 2c ; Offers Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $200.4 million versus the consensus estimate of $202.39 million.

GUIDANCE:

Myriad Genetics sees FY2026 revenue of $80.6-0.88 billion, versus the consensus of $1.53 billion.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c